# Sex-specific association between Chinese visceral adiposity index and hyperuricemia among adults: a population-based cross-sectional study in Chongqing, China

Youxing Luo<sup>1</sup>, Rui Ding<sup>2</sup>, Liling Chen<sup>3</sup>, Yanqi Hu<sup>1</sup>, Meng Xiao<sup>1</sup>, Wenge Tang<sup>3</sup>, Jinfu Qiu<sup>1</sup>, Xiang Liu<sup>4</sup>, Xianbin Ding<sup>3\*</sup>, Xiaojun Tang<sup>1\*</sup>

<sup>1</sup> School of Public Health, Research Center for Medical and Social Development, Chongqing Medical University, Chongqing 400016, China.

<sup>2</sup>First clinical medical college, Chongqing Medical University, Chongqing 400016, China.

<sup>3</sup>Institute of Chronic Non-Communicable Disease Control and Prevention, Chongqing Center for Disease Control and Prevention, Chongqing 400707, China

<sup>4</sup>Department of Epidemiology and Health Statistics, West China School of Public Health, Sichuan University, Chengdu 610041, Sichuan, China.

\*Corresponding author: Xianbin Ding, fax +86023 68803582, email xianbinding@126.com; Xiaojun fax +86023 68485008, Tang, email tangxiaojun@cqmu.edu.cn, ORCID 0000-0003-3486-1020

## E-mails of other authors:

Youxing Luo, email 2374797196@qq.com; Rui Ding, email 986027688@qq.com; Liling Chen, email 1273022824@qq.com; Yanqi Hu, email 1500221514@qq.com; Meng Xiao, email 984530150@qq.com; Wenge Tang, email 690615630@qq.com; Jinfu Qiu, email jfqiu@126.com; Xiang Liu, email new9812@126.com

Short title: Association between Chinese visceral adiposity index and hyperuricemia



This peer-reviewed article has been accepted for publication but not yet copyedited or typeset, and so may be subject to change during the production process. The article is considered published and may be cited using its DOI

## 10.1017/S0007114525000595

The British Journal of Nutrition is published by Cambridge University Press on behalf of The Nutrition Society

#### Abstract

Research on the association between the Chinese visceral adiposity index (CVAI) and hyperuricemia (HUA) is scarce, and whether the association differs by sex is unclear. This research aimed to explore sex-specific associations between CVAI and HUA and to compare CVAI's predictive performance with other adiposity indices using data from 22,171 adults (30-79 years) in the China Multi-Ethnic Cohort (CMEC) study (Chongqing region). The prevalence of HUA was 20.9% in men and 9.7% in women. Multivariable logistic regression analyses were utilized to assess the adjusted odds ratios (ORs) and 95% confidence intervals (CIs). After multivariable adjustment, CVAI was associated with HUA in men (OR Q4 vs. Q1 = 3.31, 95% CI 2.73, 4.03) and women (OR Q4 vs. Q1 = 7.20, 95% CI 5.12, 10.12). Moreover, Significant interactions were observed between BMI and CVAI on HUA in both sexes (all  $P_{\text{interaction}} < 0.001$ ), with the strongest associations in those with BMI <24.0 kg/m<sup>2</sup>. The ORs (95% CI) across different BMI groups (<24.0, 24.0–27.9, ≥28.0 kg/m<sup>2</sup>) were 1.87 (1.63, 2.13), 1.65 (1.48, 1.85), and 1.30 (1.14, 1.49) for men, and 2.76 (2.18, 3.51), 2.46 (1.98, 3.07), and 1.87 (1.47, 2.39) for women, respectively. Additionally, CVAI showed satisfactory predictive performance for HUA in women, with the largest area under the receiver operating characteristic curve (AUROC) of 0.735, but not in men (0.660). These findings suggest a close association between CVAI and HUA, particularly pronounced in those with BMI <24.0 kg/m<sup>2</sup>, and a stronger association in women than in men.

**Keywords:** Chinese visceral adiposity index; Hyperuricemia; Adiposity indices; Adults; Cross-sectional study

#### Abbreviations:

AUROC, area under the receiver operating characteristic curve; BMI, body mass index; CMI, cardiometabolic index; CMEC, China Multi-Ethnic Cohort; CVAI, Chinese visceral adiposity index; DASH, Dietary Approaches to Stop Hypertension; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FBG, fasting blood glucose; HUA, hyperuricemia; HDL-C, high-density lipoprotein cholesterol; LAP, lipid accumulation product index; LDL-C, low-density lipoprotein cholesterol; METs, metabolic equivalent tasks; NC, neck circumference; OR, odds ratios; SAT, subcutaneous adipose tissue; SBP, systolic blood pressure; SUA, serum uric acid; TC, total cholesterol; TG, triglyceride; UA, uric acid; VAI, visceral adiposity index; VAT visceral adipose tissue; WC, waist circumference; WHtR, waist-to-height ratio; XOR, xanthine oxidoreductase.

#### Introduction

Serum uric acid (SUA) is the end product of purine metabolism<sup>(1)</sup>. Hyperuricemia (HUA) may develop when there is a disturbance in purine metabolism. HUA, as an emerging public health issue, has attracted increasing attention because its prevalence has been steadily rising globally in recent decades<sup>(2, 3)</sup>. It has been closely linked to gout, hypertension, and cardiovascular disease mortality, as well as all-cause mortality<sup>(4-6)</sup>. The prevalence of HUA in China was high, estimated at approximately 20% according to a National Health Survey conducted in China between 2012 and 2017<sup>(7)</sup>. Thus, identifying modifiable HUA risk factors is vital to implement effective prevention strategies.

Obesity is recognized as a major risk factor for HUA<sup>(8-10)</sup>. More than 650 million people in the world have obesity<sup>(11)</sup>. With approximately 89.6 million individuals classified as obese<sup>(12)</sup>, China has the largest population with obesity globally. Growing evidence suggests that body fat distribution is correlated with different risks of HUA. Research has shown a stronger association between visceral adipose tissue (VAT) accumulation and the risk of HUA than abdominal subcutaneous fat across diverse populations<sup>(13-15)</sup>. Magnetic resonance imaging and computed tomography can precisely quantify the visceral fat area, but their application in large-scale epidemiological studies is constrained by their high cost and the potential risk of radiation exposure<sup>(16)</sup>. Waist circumference (WC) and waist-to-height ratio (WHtR), as traditional abdominal adiposity indices, lack the ability to distinguish between subcutaneous and visceral fats<sup>(17)</sup>. Consequently, novel abdominal adiposity indices, such as visceral adiposity index (VAI), lipid accumulation product (LAP) index, cardiometabolic index (CMI), and Chinese visceral adiposity index (CVAI) have been established to differentiate between visceral and subcutaneous adiposity. Notably, Asians have a lower body mass index (BMI) than Caucasians<sup>(18)</sup>, but they seem to be more prone to central fat deposition<sup>(19)</sup>. This means that VAI, which is used to predict visceral adiposity in Caucasians, may not adequately predict visceral adiposity in Asians. The CVAI is a recently established abdominal adiposity index in Chinese adults<sup>(20)</sup>. It combines WC, BMI, triglyceride (TG), and high-density lipoprotein cholesterol (HDL-C) while considering the influence of gender and age. It is recognized as a dependable indicator for assessing dysfunction in  $VAT^{(20)}$ . In the Chinese population, CVAI is more correlated with hypertension and prehypertension<sup>(21)</sup>,

arterial atherosclerosis<sup>(22)</sup>, and diabetes complications<sup>(23)</sup> than other obesity-related indices.

However, research investigating the associations between CVAI and HUA is scarce<sup>(24, 25)</sup>, and the predictive performance of CVAI for HUA still needs to be explored. Moreover, recent research has identified sex differences in the associations between obesity-related indices and HUA<sup>(26)</sup>. However, whether the association between CVAI and HUA differs by sex is unclear. Hence, this study aimed to explore sex-specific association between CVAI and HUA and assess the discriminative ability of CVAI for HUA in comparison with VAI, LAP, CMI, WC, and WHtR by utilizing data from the China Multi-Ethnic Cohort (CMEC) study (Chongqing region). Stratified analysis was conducted with age, smoking, drinking, spicy food intake, BMI, diabetes, and hypertension to explore the effect modifications of sociodemographic characteristics, lifestyle factors, anthropometric measurements, and health status in the relationship between CVAI and HUA.

#### Method

#### Study Population

Data for this study were obtained from the CMEC study in Chongqing region. Detailed information about the CMEC study has been introduced previously<sup>(27)</sup>. A total of 23,308 Han adults aged 30-79 years were enrolled using multistage, stratified cluster sampling methods in Chongqing Municipality, located in Southwest China, between September 2018 and February 2019. In brief, the cluster sampling method was used to select 13 districts and counties (districts and counties of the same administrative level) in Chongqing. Subsequently, based on the age and gender structure of Chongqing in 2018, stratified random sampling was employed to allocate the number of people in each district and county. Participants with missing data for SUA levels (n = 859), anthropometric parameters (n = 39), biochemical measurement indices (n = 290), and covariates (n = 39) were excluded. The remaining 22,171 participants (men: 10,355; women: 11,816) were finally included in the current analysis (Fig. S1). This study protocol was conducted in accordance with the guidelines laid down in the Declaration of Helsinki and all procedures involving human participants were approved by the Sichuan University Medical Ethical Review Board (K2016038) and the Research Ethics Committee of the Chongqing Centre for Disease Control and Prevention [2017(001)]. Written informed consent was obtained from all participants prior to participation.

#### Anthropometric and Biochemical Measurements

Anthropometric measurements, including weight (kg), height (cm), and WC (cm), were conducted by trained staff in accordance with standard protocols. Participants were checked for weight and height while standing barefoot and wearing light clothing. WC was measured using the lower edge of the tape 1 cm above the navel. BMI was calculated by dividing weight (kg) by the square of height (m). WHtR was calculated by dividing WC (cm) by height (cm).

After sitting at rest for at least 5 minutes, the participants' blood pressure was measured three times at 45-second intervals by a trained interviewer using an electronic oscillometric blood pressure measurement device (Omron HEM-7600T). The systolic blood pressure (SBP) or diastolic blood pressure (DBP) in this study was determined as the average of three measurements for SBP or DBP. Blood samples of participants were collected following an overnight fast (minimum of 8 hours) and tested at the Di'an Medical Laboratory Center. Fasting blood glucose (FBG), total cholesterol (TC), TG, low-density lipoprotein cholesterol (LDL-C), HDL-C, SUA, and creatinine were measured on an automated biochemical analyzer (HITACHI 7600 Series, Chongqing, China). The estimated glomerular filtration rate (eGFR) was computed by utilizing the newly formulated equation provided by the Chronic Kidney Disease Epidemiology Collaboration<sup>(28)</sup>.

#### Definitions

HUA was defined as having a SUA level of  $\geq$  360 µmol/L in women and  $\geq$  420 µmol/L in men<sup>(29)</sup>. The formulas for VAI<sup>(30)</sup>, CMI<sup>(31)</sup>, LAP<sup>(32)</sup>, CVAI<sup>(20)</sup> were as follows:

$$\begin{aligned} \mathrm{VAI}\,(\mathrm{men}) &= \left(\frac{\mathrm{WC}\,(\mathrm{cm})}{39.68 + 1.88 \times \mathrm{BMI}\,(\mathrm{kg/m^2})}\right) \times \left(\frac{\mathrm{TG}\,(\mathrm{mmol/L})}{1.03}\right) \times \left(\frac{1.31}{\mathrm{HDL}\,(\mathrm{mmol/L})}\right) \\ \mathrm{VAI}\,(\mathrm{women}) &= \left(\frac{\mathrm{WC}\,(\mathrm{cm})}{36.58 + 1.89 \times \mathrm{BMI}\,(\mathrm{kg/m^2})}\right) \times \left(\frac{\mathrm{TG}\,(\mathrm{mml/L})}{0.81}\right) \times \left(\frac{1.52}{\mathrm{HDL}\,(\mathrm{mmol/L})}\right) \\ \mathrm{LAP}\,(\mathrm{men}) &= (\mathrm{WC}\,(\mathrm{cm}) - 65) \times \mathrm{TG}\,(\mathrm{mmol/L}) \\ \mathrm{LAP}\,(\mathrm{women}) &= (\mathrm{WC}\,(\mathrm{cm}) - 58) \times \mathrm{TG}\,(\mathrm{mmol/L}) \\ \mathrm{CVAI}\,(\mathrm{men}) &= -267.93 + 0.68 \times \mathrm{age}\,(\mathrm{years}) + 0.03 \times \mathrm{BMI}\,(\mathrm{kg/m^2}) + 4.00 \times \mathrm{WC}\,(\mathrm{cm}) \\ &\quad + 22.00 \times \mathrm{Lg}\,\mathrm{TG}\,(\mathrm{mmol/L}) - 16.32 \times \mathrm{HDL}\,(\mathrm{mmol/L}) \end{aligned}$$

 $+39.76 \times \text{Lg TG}(\text{mmol/L}) - 11.66 \times \text{HDL}(\text{mmol/L})$ 

$$\mathrm{CMI} = \left( \frac{\mathrm{TG}\,(\mathrm{mmol/L})}{\mathrm{HDL}\,(\mathrm{mmol/L})} \right) \times \mathrm{WHtR}$$

### Assessment of Covariates

Face-to-face interviews were conducted utilizing structured questionnaires to collect detailed information on sociodemographic status (e.g., gender, age, area, marital status, and educational level), lifestyle factors (such as smoking status, drinking status, physical activity, and dietary intake), and health status. Area was divided into two categories: urban areas and rural areas, based on participants' residential addresses. Smoking was defined as having smoked  $\geq 100$  cigarettes in their lifetime, and drinking was defined as alcohol intake  $\geq 12$ times during the last year<sup>(27)</sup>. The participants' physical activity levels were assessed by aggregating the respective metabolic equivalent tasks (METs) across four domains: housework, transportation, work, and leisure<sup>(33, 34)</sup>. Dietary intake information was obtained through a food frequency questionnaire. The Dietary Approaches to Stop Hypertension (DASH) score was calculated based on the scoring method developed by Fung et al<sup>(35)</sup>. Scores of 1-5 were assigned to seven food categories (whole grains, fresh fruits, fresh vegetables, legumes, red meat products, dairy products, and sodium) in accordance with the quintile of average food intake in this study. For whole grains, fresh fruits, fresh vegetables, legumes, and dairy products, the highest quintile scored 5, and the lowest quintile scored 1. Conversely, for red meat products and sodium, this study aimed for lower intake, so the scoring pattern was reversed. Subsequently, the scores for these seven components were aggregated to yield an overall DASH score within the range of 7–35. The participants were divided into two groups ( $\leq 21$  and > 21) on the basis of median DASH score. Non-spicy eaters were defined as those who have not consumed any spicy foods in the past month. BMI was grouped into < 24.0, 24.0–27.9, and  $\geq$  28.0 kg/m<sup>2(36)</sup>. Hypertension was diagnosed as the average measurements of SBP/DBP  $\geq$  140/90 mmHg or having a self-reported history of physician-diagnosed hypertension<sup>(37)</sup>. Diabetes was defined as fasting blood glucose  $\geq 7.0$ mmol/L, glycosylated hemoglobin percentage of  $\geq 6.5\%$ , or having a self-reported history of physician-diagnosed diabetes<sup>(38)</sup>.

#### Statistical Analyses

Continuous variables, including age, physical activity, SBP, DBP, FBG, TC, TG, HDL-C, LDL-C, SUA, eGFR, BMI, WC, WHtR, VAI, CMI, and CVAI, were presented as medians and interquartile ranges (IQR) because of skewed distribution and examined using Wilcoxon two sample test, whereas categorical variables, including area, marital status, educational level, smoking status, drinking status, spicy food intake, DASH score, diabetes, and hypertension, were expressed as numbers (percentages) and were analyzed using chi-square tests. All analyses were performed separately by sex.

Logistic regression analyses were used to explore the association between CVAI and HUA and assess the odds ratios (ORs) with corresponding 95% confidence intervals (CIs) for HUA, considering CVAI as either a continuous variable (per 1-SD increment) or a categorical variable (quartiles). A series of models was employed to adjust for potential confounding factors. Model 1 included no adjustments; model 2 adjusted for age, area, educational level, marital status, smoking, drinking, spicy food intake, DASH score, and physical activity; model 3 extended these adjustments by including diabetes, hypertension, BMI, eGFR, TC, and LDL-C. The covariates included in the models were selected based on previous studies investigating the relationship between obesity and metabolic diseases<sup>(14, 21, 23, 39, 40)</sup>. Collinearity among all adjusted variables was examined, revealing no definitive evidence of multicollinearity (the variance inflation factor for all included variables was < 5; Fig. S2). The interaction between sex and CVAI on HUA in logistic regression analysis was as follows: Model outcome (y) =  $x1 + x2 + x1 \times x2 + covariates$ , where y represents HUA, x1 represents sex, x2 represents CVAI (per 1-SD),  $x1 \times x2$  was the interaction term, and covariates referred to the adjusted variables in model 3. Restricted cubic spline (RCS) analysis was conducted with four knots positioned at the 5th, 35th, 65th, and 95th percentiles of CVAI to examine potential nonlinear associations and depict the dose-response relationship of between CVAI and HUA. The predictive powers of CVAI, VAI, LAP, CMI, WC, and WHtR for HUA were evaluated using receiver operating characteristic curve. A nonparametric approach described by De Long et al.<sup>(41)</sup> was employed to compare the area under the receiver operating characteristic curve (AUROC) of CVAI in predicting HUA with those of other adiposity indices (VAI, LAP, CMI, WC, and WHtR). Stratified analyses were conducted across diverse

subgroups, including age, smoking status, drinking status, BMI, diabetes, and hypertension, to evaluate the effect modifications of CVAI on the risk of HUA and explore potential interaction effects using a multiplicative interaction term [CVAI  $\times$  (subgroups)]. Sensitivity analyses were performed by excluding participants with self-reported coronary artery disease, stroke, or cancer to validate the robustness of the results.

RCS was calculated using R (version 4.3.3, R Foundation, Boston, MA) with the "rms" package, and other analyses were conducted using SPSS (version 26.0, SPSS, Inc). A two-sided P < 0.05 was deemed statistically significant.

#### Results

#### Baseline characteristics of participants

Overall, 22,171 participants (10,355 men: 46.7%; 11,816 women: 53.3%) were included for analysis. Among them, 3320 participants (2173 men: 20.9%; 1147 women: 9.7%) were defined as having HUA. The baseline characteristics of the participants are presented in **Table 1**. The participants with HUA , regardless of sex, exhibited a higher proportion of hypertension at baseline; higher BMI, WC, WHtR, VAI, LAP, CMI, CVAI, SBP, DBP, FBG, TC, TG, LDL-C, and SUA levels; lower HDL-C and eGFR levels; and less physical activity compared to those without HUA (all P < 0.05). However, women with HUA tended to live in rural areas, showed a lower proportion of being married/cohabiting, and had a higher proportion of diabetes at baseline than those without HUA (all P < 0.05). Meanwhile, these significant differences were not observed in men with and without HUA. Moreover, women with HUA tended to be older, less educated, and non-drinkers, whereas men with HUA exhibited the opposite trend. The general characteristics of included and excluded participants were compared in Table S1. There were no significant differences in sex (Men: 47.85% vs. 46.71%; Women: 52.15% vs. 53.29%; P=0.452) and age (49.66 (IQR: 43.36–60.83) vs. 50.61 (IQR: 44.63–61.03); P=0.154) between included and excluded participants.

#### Sex-specific association between CVAI and HUA

The sex-specific association between CVAI and HUA are presented in **Table 2.** After adjusting for confounding factors, compared to the first quartile (Q1) of CVAI, the ORs with corresponding 95% CIs for HUA in the second, third, and fourth quartiles (Q2, Q3, and Q4) of CVAI were 1.67 (1.40, 1.99), 2.38 (1.98, 2.85), and 3.31 (2.73, 4.03), respectively, for men

and 2.03 (1.51, 2.73), 3.78 (2.81, 5.09), and 7.20 (5.12, 10.12), respectively, for women in model 3. Furthermore, the association between each 1-SD increase in CVAI and HUA was significantly stronger in women (OR = 2.38, 95% CI 2.09, 2.72) than in men (OR = 1.60, 95% CI 1.48, 1.71) in model 3. This sex-specific difference was statistically supported by a significant interaction between sex and CVAI on HUA ( $P_{interaction} < 0.001$ ). After participants who self-reported coronary artery disease, stroke, or cancer were excluded, the positive association between CVAI and HUA persisted (**Table S2**).

RCSs revealed a nonlinear dose–response relationship between CVAI and HUA in both sexes (all  $p_{\text{overall}} < 0.001$ ,  $p_{\text{non-linear}} < 0.05$ ; Fig. 1). In men, With the knot at 50th percentile of CVAI as the reference, the ORs with corresponding 95% CIs for the four knots of CVAI (22.10, 78.43, 109.86, and 161.22) were 0.41 (0.33, 0.50), 0.74 (0.70, 0.79), 1.30 (1.24, 1.38), and 2.12 (1.82, 2.47), respectively. The risk of HUA decreased when CVAI was <95.82, and increased when CVAI was  $\geq$ 95.82 (Fig. 1a). In women, With the knot at 50th percentile of CVAI as the reference, the ORs with corresponding 95% CIs for the four knots of CVAI (12.23, 58.93, 91.75, and 143.58) were 0.31 (0.22, 0.44), 0.61 (0.57, 0.66), 1.72 (1.57, 1.89), and 4.37 (3.47, 5.50), respectively. The risk of HUA decreased when CVAI was <75.81, and increased when CVAI was  $\geq$ 75.81(Fig. 1b).

#### Comparison of the predictive power of CVAI, VAI, LAP, CMI, WHtR, and WC for HUA

The receiver operating characteristic curve analysis showed the predictive ability of CVAI, VAI, LAP, CMI, WHtR, and WC for HUA in both sexes (**Fig. S3**). The AUROC with 95% CIs of CVAI, VAI, LAP, CMI, WHtR, and WC in men were 0.660 (0.648, 0.673), 0.695 (0.682, 0.707), 0.709 (0.697, 0.721), 0.698 (0.686, 0.711), 0.621 (0.608, 0.634), and 0.648 (0.635, 0.661), respectively, and 0.735 (0.720, 0.749), 0.713 (0.697, 0.728), 0.728 (0.713, 0.743), 0.724 (0.709, 0.739), 0.672 (0.656, 0.689), and 0.670 (0.653, 0.686), respectively, in women. Among them, LAP had the largest AUROC for HUA in men, with a cutoff of 34.03 (sensitivity: 68.3%, specificity: 64.1%), and CVAI had the largest AUROC for HUA in women, with a cutoff of 84.52 (sensitivity: 73.4%, specificity: 62.3%; **Table 3**). Additionally, the AUROC of CVAI was further compared with those of other adiposity indices among different sexes. Among men, the AUROC of CVAI statistically weaker than those of LAP, CMI, and VAI and greater than those of WC and WHtR (all P < 0.001). Among women, the

AUROC of CVAI were statistically greater than those of WC, WHtR, and VAI (all P < 0.05). Meanwhile, no significant differences were observed in the AUROC between CVAI and CMI and between CVAI and LAP (**Table 3.**). Similar results were observed in the sensitivity analysis (**Table S3**).

#### Stratified analysis

The participants were grouped based on age (< 60 and  $\geq$  60 years), smoking status (no and yes), drinking status (no and yes), spicy food (no and yes), BMI (<24.0, 24.0–27.9, and  $\geq$ 28.0 kg/m<sup>2</sup>), diabetes (no and yes), and hypertension (no and yes) to evaluate the effect modification of these factors on the association between CVAI and HUA. The positive association between CVAI and HUA persisted across various subgroups for both sexes. In both sexes, significant interactions were observed between BMI and CVAI on HUA (all P<sub>interaction</sub> <0.001). When analyses were stratified by BMI, the association between CVAI and HUA was strongest in individuals with BMI <24.0 kg/m<sup>2</sup>. Specifically, for men, the percentage increase in OR of HUA (calculated as [OR-1]×100%) was 87% in the BMI <24.0 kg/m<sup>2</sup> group (OR=1.87, 95%CI 1.63, 2.13), 65% in the BMI 24.0-27.9 kg/m<sup>2</sup> group (OR=1.65, 95%CI 1.48, 1.85), and 30% in the BMI ≥28.0 kg/m<sup>2</sup> group (OR=1.30, 95%CI 1.14, 1.49). Similarly, among women, the corresponding percentage increases were 176% (OR=2.76, 95%CI 2.18, 3.51), 146% (OR=2.46, 95%CI 1.98, 3.07), and 87% (OR=1.87, 95%CI 1.47, 2.39) across different BMI groups (Fig. 2). Moreover, a significant interaction was found between age and CVAI on HUA in women ( $P_{\text{interaction}} < 0.05$ ). However, the magnitude of the association changed minimally across different age groups, with an OR of 2.39 (95% CI 2.02, 2.80) per 1-SD increase in CVAI for women aged <60 years and 2.34 (95% CI 1.86, 3.01) for those aged  $\geq 60$  years (Fig. 2). Similar positive associations were observed in the sensitivity analysis (Fig. S4).

#### Discussion

The sex-specific association between CVAI and HUA was thoroughly explored for the first time by using a large population-based sample from Chongqing, China. A significant positive association was found between CVAI and HUA, even after adjusting for a wide range of biochemical and lifestyle factors. Sex differences were observed, with a stronger association in women than in men. Moreover, a nonlinear dose–response relationship

between CVAI and HUA was observed in both sexes. Further stratified analysis revealed that the association between CVAI and HUA was strong in both sexes with BMI <24.0 kg/m<sup>2</sup>. A significant interaction was found between age and CVAI on HUA in women. However, the magnitude of association showed minimal variation across different age groups.

This research also showed that CVAI performed well in predicting HUA in women (with the largest AUROC value), but relatively poorly in men. A Chinese study of 329 patients with type 2 diabetes revealed that except for visceral fat area, CVAI had the best diagnostic ability for HUA among other obesity indicators (BMI, neck circumference (NC), WC, and hip circumference), regardless of sex<sup>(24)</sup>. However, new adiposity indices, such as VAI, LAP, and CMI, were not considered in their study<sup>(24)</sup>. Another study including 7848 participants explored the predictive ability of different obesity indices (including new adiposity indices) for HUA, indicating that CMI had the largest AUROC in both sexes, with no significant differences in the AUROC among CVAI, CMI, and LAP for women<sup>(25)</sup>. Differences in results across studies may be attributed to variations in study populations, sample sizes, statistical analyses, and adjustment factors.

Moreover, our study found that LAP demonstrated the best predictive capability for HUA among men, with the largest AUROC. LAP's calculation formula incorporates WC and TG, which are closely related to abdominal obesity and lipid metabolism<sup>(42)</sup>. Men and women typically exhibit significant differences in lipid metabolism and visceral fat distribution<sup>(43)</sup>, potentially making LAP a more sensitive predictor of HUA in men. Previous studies have indicated that LAP has been more strongly correlated with HUA than other adiposity indices and has exhibited satisfactory predictive capability for HUA<sup>(26, 44)</sup>. However, these studies did not include CVAI. Our findings suggest that CVAI had satisfactory predictive capability for HUA in women, while LAP was effective in men. Therefore, considering sex-specific factors, combining different obesity indices may be necessary for comprehensive HUA assessment.

Furthermore, CVAI was more strongly associated with HUA in women than in men, similar to findings from a recent Taiwan study that showed a stronger correlation between obesity-related indices and HUA in women<sup>(26)</sup>. They hypothesized that this discrepancy may be attributed to higher xanthine oxidoreductase (XOR) activity in men<sup>(26)</sup>, which catalyzes the synthesis of uric acid (UA) through the oxidation of hypoxanthine and xanthine<sup>(45)</sup>.

Tsushima et al. suggested that adipose tissue is rich in XOR, which plays a key role in UA production utilizing a mouse model<sup>(46)</sup>. A previous study has indicated higher levels of xanthine, hypoxanthine, and plasma XOR in men than in women, with hypoxanthine concentration independently associated with obesity<sup>(47)</sup>. Thus, higher XOR activity in men may explain the weaker correlation between obesity indicators and HUA. Additionally, previous studies have found a stronger association between visceral fat and adverse metabolic outcomes in women than in men, possibly due to sex differences in adipocyte size, basal lipolysis, and fatty acid oxidation rates<sup>(48, 49)</sup>. Women tended to have lower levels of basal fatty acid oxidation than men, making them more susceptible to metabolic disturbances<sup>(50)</sup>. Further studies are needed to explore the sex physiology associated with HUA and obesity.

Additionally, the stratified analysis suggested that BMI could potentially modulate the association between CVAI and HUA, a more pronounced interaction effect of CVAI on HUA was observed in individuals with BMI < 24.0 kg/m<sup>2</sup>. BMI, serving as a general obesity metric, is incapable of evaluating specific regional adipose tissue content. For instance, a computed tomography study demonstrated that individuals with normal BMI (18.5–25.0 kg/m<sup>2</sup>) exhibited a high proportion of visceral obesity—a condition strongly linked to metabolic disorders<sup>(51)</sup>. In Asians, visceral obesity has emerged as a more reliable indicator of obesity than BMI<sup>(52)</sup>. Research has shown stronger correlations between abdominal obesity indices (WC, VAI, LAP, and CVAI) and incident cardiovascular events in the subgroup with BMI <25 kg/m<sup>2</sup> compared to the overweight/obese group<sup>(17)</sup>. Another study had similar findings<sup>(23)</sup>. These findings collectively indicate that BMI inadequately captures visceral fat accumulation—a key factor of obesity-related diseases like HUA and cardiovascular disease. To the best of the authors' knowledge, this study was the first stratified analysis conducted to explore the relationship between CVAI and HUA.

SUA is produced as a result of purine metabolism, with its levels primarily governed by the balance between UA production and excretion<sup>(53)</sup>. Our study found an association between CVAI and HUA. The mechanisms may include: (1) The buildup of obese adipose tissue in individuals with obesity can increase free fatty acid levels, which are closely associated with de-novo purine synthesis, thereby promoting SUA production<sup>(15, 46)</sup>. (2) Adiposity is associated with hyperinsulinemia and insulin resistance, which may affect the

reabsorption of sodium and UA on renal tubules, leading to reduced UA excretion and increased UA levels, ultimately fostering the development of HUA<sup>(54-56)</sup>. (3) VAT exhibits a higher level of lipolysis than subcutaneous adipose tissue. The higher the lipolytic activity of VAT, the greater the flow of free fatty acids to the liver, affecting purine metabolism and accelerating UA production<sup>(57)</sup>.

The key strengths of this study include that it is the first to explore the sex-specific association between CVAI and HUA in a large population-based sample from Chongqing, as well as the first to examine their dose-response relationship, which was not considered in previous research. However, several limitations should be noted. First, as a cross-sectional study, causality cannot be determined. Second, self-reported data on variables, such as physical activity, smoking, drinking, dietary habits, may introduce reporting and recall biases. Third, participants with HUA may have altered their lifestyles to reduce visceral fat accumulation, potentially underestimating the association. Therefore, longitudinal studies are warranted to validate these findings. Finally, since the study was conducted exclusively in Chongqing, China, the results may not be generalizable to broader Chinese populations.

#### Conclusions

The research findings indicated a close association between CVAI and HUA in adults aged 30–79 years in Chongqing, China, particularly pronounced in those with BMI <24.0 kg/m<sup>2</sup>, and with sex differences. A stronger association was found in women than in men. For women, CVAI served as a satisfactory predictor of HUA, while for men, LAP proved to be a more effective predictor. Considering the sex factor, different obesity-related indices should be combined to provide a comprehensive evaluation for HUA.

#### Acknowledgements

We are very grateful to all the participants in this study and to all team members for their support of this study.

This work was supported by the National Key Research and Development Program of China (Grant number 2017YFC0907303), the Medical Scientific Research Project of Chongqing Health Commission (Grant number 2022WSJK021), and the Key Research and Development Project of the Science and Technology of Sichuan Province (Grant number 2020YFS0216).

The authors' contributions are as follows: X. D., X. T., W. T., J. Q. and X. L. designed research; Y. L., R. D, L. C., Y. H. and M. X. conducted research; W. T., J. Q. and X. L. provided essential reagents and materials; Y. L., R. D., L. C., Y. H. and M. X. analyzed data; Y. L. wrote the paper; X. D. and X. T. reviewed and revised the manuscript; Y. L., X. D. and X. T. had primary responsibility for final content. All authors read and approved the final manuscript for submission.

The authors declared that they had no conflicts of interest with the contents of this article.

#### **Supplementary Materials**

Supplementary materials are available from the file entitled "Supplementary data".

#### References

- Wu XW, Lee CC, Muzny DM, *et al.* (1989) Urate oxidase: primary structure and evolutionary implications. *Proceedings of the National Academy of Sciences* 86, 9412-9416.
- 2. Singh G, Lingala B, Mithal A (2019) Gout and hyperuricaemia in the USA: prevalence and trends. *Rheumatology* **58**, 2177-2180.
- Ting K, Gill TK, Keen H, et al. (2016) Prevalence and associations of gout and hyperuricaemia: results from an Australian population-based study. *Internal Medicine Journal* 46, 566-573.
- 4. Dalbeth N, Gosling AL, Gaffo A, et al. (2021) Gout. Lancet 397, 1843-1855.
- Grayson PC, Kim SY, LaValley M, et al. (2011) Hyperuricemia and incident hypertension: A systematic review and meta-analysis. Arthritis Care & Research 63, 102-110.
- Zhao G, Huang L, Song M, *et al.* (2013) Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: a meta-analysis of prospective studies. *Atherosclerosis* 231, 61-68.
- 7. He H, Pan L, Ren X, *et al.* (2021) The Effect of Body Weight and Alcohol Consumption on Hyperuricemia and Their Population Attributable Fractions: A National Health

Survey in China. Obesity Facts 15, 216-227.


- 8. Dehlin M, Jacobsson L, Roddy E (2020) Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. *Nat Rev Rheumatol* **16**, 380-390.
- 9. Song P, Wang H, Xia W, *et al.* (2018) Prevalence and correlates of hyperuricemia in the middle-aged and older adults in China. *Sci Rep* **8**, 4314.
- Dong X, Zhang H, Wang F, *et al.* (2020) Epidemiology and prevalence of hyperuricemia among men and women in Chinese rural population: The Henan Rural Cohort Study. *Mod Rheumatol* 30, 910-920.
- Xiao ML, Zhong HL, Lin HR, *et al.* (2022) Higher serum vitamin A is associated with a worsened progression of non-alcoholic fatty liver disease in adults: a prospective study. *Food Funct* 13, 970-977.
- NCD Risk Factor Collaboration (NCD-RisC) (2016) Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. *Lancet* 387, 1377-1396.
- Matsuura F, Yamashita S, Nakamura T, *et al.* (1998) Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. *Metabolism* 47, 929-933.
- 14. Bai R, Ying X, Shen J, *et al.* (2022) The visceral and liver fat are significantly associated with the prevalence of hyperuricemia among middle age and elderly people: A cross-sectional study in Chongqing, China. *Front Nutr* 9, 961792.
- 15. Takahashi S, Yamamoto T, Tsutsumi Z, *et al.* (1997) Close correlation between visceral fat accumulation and uric acid metabolism in healthy men. *Metabolism* **46**, 1162-1165.
- Luo Y, Ma X, Shen Y, *et al.* (2014) Positive relationship between serum low-density lipoprotein cholesterol levels and visceral fat in a Chinese nondiabetic population. *PLoS One* 9, e112715.
- Qiao T, Luo T, Pei H, *et al.* (2022) Association between abdominal obesity indices and risk of cardiovascular events in Chinese populations with type 2 diabetes: a prospective cohort study. *Cardiovasc Diabetol* 21, 225.

- Deurenberg P, Deurenberg-Yap M, Guricci S (2002) Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship. *Obes Rev* 3, 141-146.
- Camhi SM, Bray GA, Bouchard C, *et al.* (2011) The relationship of waist circumference and BMI to visceral, subcutaneous, and total body fat: sex and race differences. *Obesity* (*Silver Spring*) 19, 402-408.
- 20. Xia MF, Chen Y, Lin HD, *et al.* (2016) A indicator of visceral adipose dysfunction to evaluate metabolic health in adult Chinese. *Sci Rep* **6**, 38214.
- 21. Li B, Wang J, Zhou X, et al. (2022) Chinese Visceral Adiposity Index Is More Closely Associated With Hypertension and Prehypertension Than Traditional Adiposity Indices in Chinese Population: Results From the REACTION Study. *Front Endocrinol* (*Lausanne*) 13, 921997.
- Huang YC, Huang JC, Lin CI, *et al.* (2021) Comparison of Innovative and Traditional Cardiometabolic Indices in Estimating Atherosclerotic Cardiovascular Disease Risk in Adults. *Diagnostics (Basel)* 11.
- 23. Wan H, Wang Y, Xiang Q, *et al.* (2020) Associations between abdominal obesity indices and diabetic complications: Chinese visceral adiposity index and neck circumference. *Cardiovasc Diabetol* 19, 118.
- Wang D, Wang X, Yin F (2022) Correlation between Chinese visceral adipose index and type 2 diabetes mellitus complicated by hyperuricemia. *Hebei Medical Journal* 44, 1699-1701,1705 (in Chinese).
- 25. Zhang H, Qu S, Qiu H, *et al.* (2023) Predictive ability of different obesity index for hyperuricemia. *Modern Preventive Medicine* **50**, 1908-1915 (in Chinese).
- 26. Su SY, Lin TH, Liu YH, et al. (2023) Sex Difference in the Associations among Obesity-Related Indices with Hyperuricemia in a Large Taiwanese Population Study. *Nutrients* 15.
- 27. Zhao X, Hong F, Yin J, *et al.* (2021) Cohort Profile: the China Multi-Ethnic Cohort (CMEC) study. *Int J Epidemiol* **50**, 721-7211.
- 28. Levey AS, Stevens LA, Schmid CH, *et al.* (2009) A new equation to estimate glomerular filtration rate. *Ann Intern Med* **150**, 604-612.

- Feig DI, Kang DH, Johnson RJ (2008) Uric acid and cardiovascular risk. N Engl J Med
  359, 1811-1821.
- Amato MC, Giordano C, Galia M, *et al.* (2010) Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. *Diabetes Care* 33, 920-922.
- Wakabayashi I, Daimon T (2015) The "cardiometabolic index" as a new marker determined by adiposity and blood lipids for discrimination of diabetes mellitus. *Clin Chim Acta* 438, 274-278.
- 32. Kahn HS (2005) The "lipid accumulation product" performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord 5, 26.
- 33. Ao L, Zhou J, Han M, *et al.* (2022) The joint effects of physical activity and air pollution on type 2 diabetes in older adults. *BMC Geriatr* **22**, 472.
- 34. Ainsworth BE, Haskell WL, Whitt MC, *et al.* (2000) Compendium of physical activities: an update of activity codes and MET intensities. *Med Sci Sports Exerc* 32, S498-504.
- 35. Fung TT, Chiuve SE, McCullough ML, et al. (2008) Adherence to a DASH-style diet and risk of coronary heart disease and stroke in women. Arch Intern Med 168, 713-720.
- WS/T 428-2013; Criteria of Weight for Adults. *Standard Press of China:* Beijing, China, 2013.
- 37. Joint Committee for Guideline Revision (2019) 2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension. J Geriatr Cardiol 16, 182-241.
- American Diabetes Association (2017) 2. Classification and Diagnosis of Diabetes. Diabetes Care 40, S11-s24.
- 39. Huang X, Jiang X, Wang L, *et al.* (2019) Visceral adipose accumulation increased the risk of hyperuricemia among middle-aged and elderly adults: a population-based study. J Transl Med 17, 341.

- Dong X, Li Y, Yang K, *et al.* (2020) Mediation effect of body mass index on the association between spicy food intake and hyperuricemia in rural Chinese adults: the Henan rural cohort study. *BMC Public Health* 20, 1629.
- DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics* 44, 837-845.
- 42. Mirmiran P, Bahadoran Z, Azizi F (2014) Lipid accumulation product is associated with insulin resistance, lipid peroxidation, and systemic inflammation in type 2 diabetic patients. *Endocrinol Metab (Seoul)* **29**, 443-449.
- Link JC, Reue K (2017) Genetic Basis for Sex Differences in Obesity and Lipid Metabolism. *Annu Rev Nutr* 37, 225-245.
- 44. Liu XZ, Li HH, Huang S, *et al.* (2019) Association between hyperuricemia and nontraditional adiposity indices. *Clin Rheumatol* **38**, 1055-1062.
- 45. Battelli MG, Bortolotti M, Polito L, *et al.* (2018) The role of xanthine oxidoreductase and uric acid in metabolic syndrome. *Biochim Biophys Acta Mol Basis Dis* **1864**, 2557-2565.
- 46. Tsushima Y, Nishizawa H, Tochino Y, *et al.* (2013) Uric acid secretion from adipose tissue and its increase in obesity. *J Biol Chem* **288**, 27138-27149.
- 47. Furuhashi M, Koyama M, Higashiura Y, *et al.* (2020) Differential regulation of hypoxanthine and xanthine by obesity in a general population. *J Diabetes Investig* 11, 878-887.
- Kanaya AM, Harris T, Goodpaster BH, *et al.* (2004) Adipocytokines attenuate the association between visceral adiposity and diabetes in older adults. *Diabetes Care* 27, 1375-1380.
- Tanaka S, Togashi K, Rankinen T, *et al.* (2004) Sex differences in the relationships of abdominal fat to cardiovascular disease risk among normal-weight white subjects. *Int J Obes Relat Metab Disord* 28, 320-323.
- 50. Blaak E (2001) Gender differences in fat metabolism. *Curr Opin Clin Nutr Metab Care*4, 499-502.

- 51. Kong M, Xu M, Zhou Y, et al. (2022) Assessing Visceral Obesity and Abdominal Adipose Tissue Distribution in Healthy Populations Based on Computed Tomography: A Large Multicenter Cross-Sectional Study. Front Nutr 9, 871697.
- Kang J, Baek SE, Kim T, *et al.* (2012) Impact of fat obesity on laparoscopic total mesorectal excision: more reliable indicator than body mass index. *Int J Colorectal Dis* 27, 497-505.
- Fathallah-Shaykh SA, Cramer MT (2014) Uric acid and the kidney. *Pediatr Nephrol* 29, 999-1008.
- 54. Fryk E, Olausson J, Mossberg K, et al. (2021) Hyperinsulinemia and insulin resistance in the obese may develop as part of a homeostatic response to elevated free fatty acids: A mechanistic case-control and a population-based cohort study. *EBioMedicine* 65, 103264.
- 55. Liu H, Song X, Zhu J, et al. (2022) The elevated visceral adiposity index increases the risk of hyperuricemia in Chinese hypertensive patients: A cross-sectional study. Front Endocrinol (Lausanne) 13, 1038971.
- 56. Quiñones Galvan A, Natali A, Baldi S, et al. (1995) Effect of insulin on uric acid excretion in humans. Am J Physiol 268, E1-5.
- 57. Seyed-Sadjadi N, Berg J, Bilgin AA, *et al.* (2017) Visceral fat mass: is it the link between uric acid and diabetes risk? *Lipids Health Dis* **16**, 142.



**Fig. 1.** Dose-response relationship between Chinese visceral adiposity index (CVAI) and hyperuricemia (HUA) among adults enrolled in the Chinese Multi-Ethnic Cohort study, using restricted cubic splines based on a logistic regression model. The plot shows a non-linear relatonship between CVAI and HUA. Data are odds ratio (OR) and 95% confidence interval (CI), Solid lines indicate OR, shadow shape indicates 95% CI. <sup>a</sup>There was a nonlinear dose-response relationship between CVAI and the risk of HUA in men ( $p_{\text{overall}} < 0.001$ ,  $p_{\text{non-linear}} = 0.002$ ). <sup>b</sup>There was a nonlinear dose-response relationship between CVAI and the risk of HUA in women ( $p_{\text{overall}} < 0.001$ ,  $p_{\text{non-linear}} < 0.001$ ).

Men Subgroup		OR(95%CD)	P	P for interaction	Women Subgroup		OR(95%CI)	P	P for interaction
Age	1	******		0.596	Age				0.009
<60	+	1.52(1.40,1.65)	<0.001		<60		2.39(2.02,2.80)	< 0.001	
≥60		1.86(1.61,2.15)	<0.001		260		2.34(1.86,3.01)	<0.001	
Smoking status		0010021010000000		0.188	Smoking status				0.820
No	+	1.43(1.29,1.58)	< 0.001		No		2.41(2.11.2.76)	<0.001	
Yes		1.78(1.61,1.97)	<0.001		Yes		1.04(0.27,3.93)	0.564	
Drinking status	0			0.290	Drinking status				0.533
No		1.58(1.38,1.82)	<0.001		No		2.40(2.02,2.84)	<0.001	
Yes	-	1.61(1.48,1.75)	<0.001		Yes		2.40(1.93,2.99)	< 0.001	
Spicy food intake		101000000000000000000000000000000000000		0.471	Spicy food intake	10000			0.197
No		1.45(1.20,1.75)	<0.001		No		2.35(1.67,3.32)	< 0.001	
Yes	+	1.63(1.50,1.76)	<0.001		Yes		2.38(2.06,2.76)	<0.001	
BMI				<0.001	BMI	1.773 (A.27)			<0.001
<24		1.87(1.63,2.13)	< 0.001		<24		2.76(2.18,3.51)	<0.001	
24-27.9		1.65(1.48,1.85)			24-27.9		2.46(1.98,3.07)		
≥28	-	1.30(1.14,1.49)	<0.001		≥28		1.87(1.47,2.39)	<0.001	
Diabetes				0.464	Diabetes				0.251
No	+	1.57(1.46,1.70)	<0.001		No		2.34(2.03,2.69)	<0.001	
Yes		1.75(1.41,2.19)	<0.001		Yes		2.45(1.61.3.71)	< 0.001	
Hypertension				0.544	Hypertension				0.300
No		1.54(1.40,1.70)	< 0.001		No		2.29(1.91.2.73)	< 0.001	
Yes		1.66(1.50,1.85)	<0.001		Yes		2,52(2:05,3.10)	<0.001	

**Fig. 2.** Association between Chinese visceral adiposity index (CVAI) (per-SD increase) and hyperuricemia (HUA) among adults enrolled in the Chinese Multi-Ethnic Cohort study, stratified by age, smoking, drinking, spicy food, body mass index (BMI), diabetes, and hypertension, using logistic regression model. The model was adjusted for age, area, education level, martial status, smoking, drinking, spicy food intake, DASH score, physical activity, diabetes, hypertensions, BMI, eGFR, TC and LDL-C, except for stratify. Data are odds ratio (OR) and 95% confidence interval (CI). BMI, body mass index; CVAI, Chinese visceral adiposity index; DASH, Dietary Approaches to Stop Hypertension; eGFR, estimated glomerular filtration rate; HUA, hyperuricemia; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol.

Fig. S1. Flow chart of the selection of study participants.

Fig. S2. The variance inflation factors for all included variables in model 3.

model 3: included age, area, education level, marital status, smoking, drinking, spicy food intake, DASH score, physical activity, diabetes, hypertension, BMI, eGFR, TC, and LDL-C.

**Fig. S3.** Receiver operating characteristic curve of waist circumference (WC), waist-to-height ratio (WHtR), visceral adiposity index (VAI), lipid accumulation product index (LAP), cardiometabolic index (CMI), and Chinese visceral adiposity index (CVAI) for predicting hyperuricemia (HUA) among men and women enrolled in the Chinese Multi-Ethnic Cohort study.

**Fig. S4.** Sensitivity analyses for association between Chinese visceral adiposity index (CVAI) (per-SD increase) and hyperuricemia (HUA) among adults enrolled in the Chinese Multi-Ethnic Cohort study, stratified by age, smoking, drinking, spicy food, body mass index (BMI), diabetes, and hypertension, using logistic regression model.

Table 1. Baseline characteristics of 22,171 participants with and without hyperuricemia (HUA), stratified by sex, recruited from the Chinese

Multi-Ethnic Cohort study in Chongqing, China

(Median and interquartile ranges	(IQR); numbers and percentages)
----------------------------------	---------------------------------

	Men (n=10,355)					Women (n=11,816)				_
	non-HUA (n=8182)		HUA (n=2173)		-	non-HUA (n=10,669)		HUA (n=1147)		_
Variables	Media n	IQR	Media n	IQR	Р	Media n	IQR	Media n	IQR	P
Age(years)	51.00	44.00-62.00	48.00	41.00–58.00	< 0.001	49.00	43.00–58.00	55.00	47.00–65.00	< 0.001
Area(n,%)					0.168					0.040
Urban	2354	28.77	658	30.28		3051	28.60	295	25.72	
Rural	5828	71.23	1515	69.72		7618	71.40	852	74.28	
Marital status(n,%)					0.625					< 0.001
Married/cohabiting	7412	90.59	1961	90.24		9200	86.23	921	80.30	
Others	770	9.41	212	9.76		1469	13.77	226	19.70	
Education(n,%)					<					<

					0.001					0.001
Primary school or below	2454	29.99	468	21.54		3860	36.18	474	41.33	
Junior high school	2742	33.51	701	32.26		3328	31.19	360	31.39	
High school or above	2986	36.49	1004	46.20		3481	32.63	313	27.29	
Smoking(n,%)					0.313					0.391
No	3606	44.07	984	45.28		10517	98.58	1127	98.26	
Yes	4576	55.93	1189	54.72		152	1.42	20	1.74	
					<					
Drinking(%)					0.001					0.006
No	2499	30.54	527	24.25		6388	59.87	735	64.08	
Yes	5683	69.46	1646	75.75		4281	40.13	412	35.92	
					<					
Spicy food intake (n,%)										0.182
					0.001					
No	1188	14.52	230	10.58		1528	14.32	181	15.78	
Yes	6994	85.48	1943	89.42		9141	85.68	966	84.22	
DASH score(n,%)					0.397					0.700
≤21	5029	61.46	1314	60.47		5003	46.89	531	46.29	
>21	3153	38.54	859	39.53		5666	53.11	616	53.71	

Physical activity	26.00	17.10-40.01	24.17	16.97–36.02	<	24.22	16.60–36.22	21.9	15.05-32.76	<
(METs/h/day)	20.00	1,110 10101	2,	1007 20102	0.001	2	10.00 20.22		10100 02110	0.001
$\mathbf{Diabatas}(\mathbf{n}, 0')$					0.137					<
Diabetes(n,%)					0.137					0.001
No	7250	88.61	1950	89.74		9868	92.49	969	84.48	
Yes	932	11.39	223	10.26		801	7.51	178	15.52	
University of the second se					<					<
Hypertension(n,%)					0.001					0.001
No	5108	62.43	1122	51.63		7590	71.14	564	49.17	
Yes	3074	37.57	1051	48.37		3079	28.86	583	50.83	
$ODD(\dots, U_{n})$	129.6	119.67–142.	122.00	123.33–145.	<	124.00	113.00–139.3	135.0	122.00–149.	<
SBP(mmHg)	7	33	133.00	67	0.001	124.00	3	0	33	0.001
					<					<
DBP(mmHg)	80.33	73.33–87.67	83.67	76.67–91.33	0.001	74.67	68-82.33	79.33	72.33–86.67	0.001
					<					<
FBG(mmol/L)	5.30	4.95–5.78	5.38	5.02-5.90		5.20	4.91–5.60	5.53	5.13–6.14	
					0.001					0.001

TC(mmol/L)	4.91	4.35–5.51	5.10	4.49–5.72	<	4.89	4.32–5.53	5.19	4.56–5.9	<
					0.001					0.001
TG(mmol/L)	1.28	0.90–1.88	1.95	1.34–2.90	<	1.12	0.84–1.57	1.66	1.17–2.31	<
TO(IIIII0I/L)					0.001	1.12	0.84–1.37			0.001
UDL C(mmal/L)	1 40	1 17 1 70	1.23	1.04–1.48	<	1 (7	1 41 1 05	1 4 4	1.19–1.69	<
HDL-C(mmol/L)	1.40	1.17–1.70			0.001	1.67	1.41–1.95	1.44		0.001
										<
LDL-C(mmol/L)	2.74	2.23-3.28	2.81	2.28–3.36	0.016	2.60	2.11–3.15	2.86	2.33–3.48	0.001
	330.0	293.00–369.		437.00–503.	<		226.00-297.0	390.0	371.00–419.	<
		2/3.00 30/.		10/100 0001	•		==0.00 =>0			
SUA(umol/L)	0	00	462.00	00	0.001	260.00	0	0	00	0.001
	0						0	0		
SUA(umol/L) eGFR(ml/min/1.73m <sup>2</sup> )		00	462.00 92.98	00	0.001	260.00 103.01			00	0.001
eGFR(ml/min/1.73m <sup>2</sup> )	0	00 88.43–105.0 4	92.98	00 80.62–102.5	0.001 <	103.01	0	0 90.86	00 78.67–102.1	0.001 <
	0	00 88.43–105.0		00 80.62–102.5	0.001 < 0.001 <		0	0	00 78.67–102.1	0.001 < 0.001 <
eGFR(ml/min/1.73m <sup>2</sup> )	0 97.43	00 88.43–105.0 4	92.98	00 80.62–102.5 4	0.001 < 0.001 < 0.001	103.01	0 93.10–110.36	0 90.86	00 78.67–102.1 7	0.001 < 0.001 < 0.001
eGFR(ml/min/1.73m <sup>2</sup> )	0 97.43	00 88.43–105.0 4	92.98	00 80.62–102.5 4	0.001 < 0.001 <	103.01	0 93.10–110.36	0 90.86	00 78.67–102.1 7	0.001 < 0.001 <

WHtR	0.52	0.48-0.55	0.54	0.51–0.57	<	0.52	0.48-0.56	0.56	0.51-0.60	<
					0.001					0.001
VAI	1.13	0.69–1.93	2.05	1.19–3.41	<	1.21	0.81–1.95	2.13	1.34–3.43	<
V / 11	1.15	0.09 1.95	2.05	1.17 5.11	0.001	1.21	0.01 1.75	2.13	1.51 5.15	0.001
LAP	25.57	14.04–43.68	48.50	28.65–77.47	<	23.92	14.25–39.32	45.36	28.06-70.52	<
	23.37	14.04 43.00	40.50	20.03 11.41	0.001	23.72	17.25 57.52	45.50	20.00 70.52	0.001
СМІ	0.47	0.28–0.81	0.87	0.50–1.47	<	0.35	0.22-0.57	0.64	0.40-1.06	<
Civil	0.47	0.20-0.01	0.87	0.30-1.47	0.001	0.55	0.22-0.37	0.04	0.40-1.00	0.001
CMAL	00 00	61.20–116.1	112 67	87.27–136.5	<	71 50	44.99 00.29	107.8	81.89–132.7	<
CVAI	89.89	9	112.67	0	0.001	71.58	44.88–99.38	8	5	0.001

DASH, dietary approaches to stop hypertension; METs, metabolic equivalent values; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; TC, total cholesterol; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; SUA, serum uric acid; eGFR, estimated glomerular filtration rate; BMI, body mass index; WC, waist circumference; WHtR, waist-to-height ratio; VAI, visceral adiposity index; CVAI, Chinese visceral adiposity index; LAP, lipid accumulation product index; CMI, cardiometabolic index; HUA, hyperuricemia. others in marital status including separated/divorced/widowed/unmarried.

**Table 2.** Association between Chinese visceral adiposity index (CVAI) and hyperuricemia (HUA) among adults enrolled in the Chinese Multi-Ethnic Cohort study, stratified by sex, according to CVAI as categorical (quartile) or continuous variables, using logistic regression (Odds ratios (OR) and 95% confidence intervals (CI); numbers)

CIAI		Model 1	Model 2	Model 3
CVAI	No. of cases/participants –	OR(95%CI)	OR(95%CI)	OR(95%CI)
Men				
CVAI (Quartiles)				
Q1(≤65.86)	258/2589	1.00(ref)	1.00(ref)	1.00(ref)
Q2(65.87-95.05)	421/2590	1.75(1.49,2.07)*	1.71(1.45,2.02)*	1.67(1.40,1.99)*
Q3(95.06-121.21)	610/2588	2.79(2.38,3.26)*	2.74(2.33,3.21)*	2.38(1.98,2.85)*
Q4(>121.21)	884/2588	4.69(4.03,5.46)*	4.75(4.07,5.55)*	3.31(2.73,4.03)*
<i>P</i> for trend		< 0.001	< 0.001	< 0.001
CVAI (per-SD increase)	2173/10,355	1.80(1.71,1.89)*	1.82(1.73,1.92)*	1.60(1.48,1.71)*
Women				
CVAI (Quartiles)				
Q1(≤47.19)	74/2956	1.00(ref)	1.00(ref)	1.00(ref)
Q2(47.20-75.30)	151/2952	2.10(1.58,2.79)*	2.29(1.72,3.04)	2.03(1.51,2.73)*
Q3(75.31-104.20)	297/2954	4.35(3.36,5.65)*	5.04(3.86,6.58)	3.78(2.81,5.09)*
Q4(>104.20)	625/2954	10.45(8.16,13.38)*	13.01(9.92,17.06)*	7.20(5.12,10.12)*
<i>P</i> for trend		< 0.001	< 0.001	< 0.001
CVAI (per-SD increase)	1147/11,816	2.45(2.29,2.63)*	2.83(2.59,3.09)*	2.38(2.09,2.72)*

Model 1: without adjustments. Model 2: adjusted for age, area, education level, marital status, smoking, drinking, spicy food intake, DASH score, and physical activity. Model 3: further adjusted for diabetes, hypertension, BMI, eGFR, TC, and LDL-C. SD, standard deviation. \*P < 0.001.

(N=10,355) and wome	en (N=11,816) enrolled in the C	Chinese Multi	-Ethnic Cohort study			
Adiposity indices	AUROC(95%CI)	Cutoff	Sensitivity (%)	Specificity (%)	Youden index (%)	Р
Men						
WC	0.648(0.635-0.661)	89.95	52.5	69.5	22.0	< 0.001
WHtR	0.621(0.608-0.634)	0.52	65.5	52.4	17.9	< 0.001
VAI	0.695(0.682-0.707)	1.38	69.5	60.0	29.5	< 0.001
LAP	0.709(0.697-0.721)	34.03	68.3	64.1	32.4	< 0.001
CMI	0.698(0.686-0.711)	0.54	72.1	57.2	29.3	< 0.001
CVAI	0.660(0.648-0.673)	101.22	62.8	61.3	24.1	-
Women						
WC	0.670(0.653-0.686)	83.75	58.0	68.3	26.3	< 0.001
WHtR	0.672(0.656-0.689)	0.53	67.0	58.4	25.4	< 0.001
VAI	0.713(0.697-0.728)	1.55	68.7	64.2	32.9	0.003
LAP	0.728(0.713-0.743)	32.67	68.4	66.7	35.1	0.199
CMI	0.724(0.709-0.739)	0.47	68.3	66.9	35.2	0.106
CVAI	0.735(0.720-0.749)	84.52	73.4	62.3	35.7	-

**Table 3.** Area under the receiver operating characteristic curve (AUROC) of adiposity indices for predicting hyperuricemia (HUA) among men (N=10,355) and women (N=11,816) enrolled in the Chinese Multi-Ethnic Cohort study

WC, waist circumference; WHtR, waist-to-height ratio; VAI, visceral adiposity index; LAP, lipid accumulation product; CMI, cardiometabolic index; CVAI, Chinese visceral adiposity index; HUA, hyperuricemia; AUROC, area under the receiver operating characteristic curve; CI, confidence intervals.